In vitro identification and characterization of CD133poscancer stem-like cells in anaplastic thyroid carcinoma cell lines

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Zito, Giovanni ^a   Richiusa, Plerina ^a   Bommarito, Alessandra ^a   Carissimi, Elvira ^a   Russo, Leonardo ^a   Coppola, Antonina ^a   Zerilli, Monica ^a   Rodolico, Vito ^a   Criscimanna, Angela ^a   Amato, Marco ^a   Pizzolanti, Giuseppe ^a   Galluzzo, Aldo ^a   Giordano, Carla ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD133 ANTIGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FIBRONECTIN; OCTAMER TRANSCRIPTION FACTOR 4; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN; THYROID TRANSCRIPTION FACTOR 1; ANTINEOPLASTIC AGENT; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; NUCLEAR PROTEIN; ONCOFETAL FIBRONECTIN; PEPTIDE; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CD133+ CELL SELECTION; CELL PROLIFERATION; CELL RENEWAL; CELL SELECTION; CELL STRAIN; CELL STRAIN ARO; CELL STRAIN FRO; CELL STRAIN KAT 18; CELL STRAIN KAT 4; CELL STRAIN TAD 2; COLONY FORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA; CARCINOMA; CELL SEPARATION; CULTURE TECHNIQUE; DRUG EFFECT; DRUG SCREENING; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FIBRONECTINS; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PEPTIDES; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY;

EID: 56149120213     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003544     Document Type: Article

References (43)

1. AACE/AME Task Force on Thyroid Nodules American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006; 12(1): 63-102.
2. Thomas T, Nowka K, Lan L, Derwahl M (2006) Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid. Thyroid 16: 537-544.
3. Scholer HR, Ruppert S, Suzuki N (1990) New type of POU domain in germ line-specific protein OCT-4. Nature 344: 435-439.
4. Lin RY (2007) New insights into Thyroid Stem cells. Thyroid 17(10): 1-5.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859): 105-11.
6. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumor initiating cells. Nature 432: 396-401.
8. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer stem cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511.
9. +prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708.
10. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, et al. (2004) Gastric cancer originating from bone marrow-derived cells. Science 306: 1568-1571.
11. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, et al. (2005) Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835.
12. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445: 106-110.
13. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ (2005) Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5: 899-904.
14. +HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 12: 1749-1758.
15. Baguley BC (2006) Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Patents Anticancer Drug Discov 1: 121-127.
16. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru, et al. (2007) Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 148: 1797-1803.
17. Takano T, Amino N (2005) Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma. Thyroid 15(5): 432-439.
18. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
19. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, et al. (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021.
20. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F (2007) Human embryonic and neuronal stem markers in retinoblastoma. Mol Vis 8: 823-832.
21. Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment. J Pathol 214: 3-9.
22. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, et al. (1998) Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95(3): 379-91.
23. Zangrossi S, Barabese M, Broggini M, Giordano R, D'Erasmo M, et al. (2007) OCT-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells 25: 1675-1680.
24. Liedtke S, Enczmann J, Waclawczyk S, Wernet P, Kögler G (2007) Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 1(4): 364-366.
25. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461-463.
26. Takano T, Ito Y, Matsuzuka F, Miya A, Kobayashi K, Yoshida H, et al. (2007) Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma. Jpn J Clin Oncol 37: 647-651.
27. Liu D, Hu S, Hou P, Jiang D, Condourius S, et al. (2007) Suppression of BRAF/MEK/MAP kinase restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 13: 1341-1349.
28. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J (2007) qBase relative quantification framework and software for management and automated analysis for real-time quantitative PCR data. Genome Biology 8: R19.
29. Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18: 460-466.
30. Cho W, Clarke MF (2008) Recent advances in cancer stem cells. Curr Opin Genet Dev 18: 1-6.
31. Clarke MF, Fuller M (2006) Stem cells and cancer: two faces of eve. Cell 124: 1111-1115.
32. Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284.
33. Takano T (2007) Fetal cell carcinogenesis of the thyroid: theory and practice. Seminars in Cancer Biol 17: 233-240.
34. Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132(7): 2542-56.
35. Ordonez NG (2000) Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol 7: 123-7.
36. Alderden AR, Hall DM, Hambley WT (2006) The discovery and development of cisplatin. J Chem Ed 83: 728-724.
37. Momparler RL, Karon M, Siegel SE, Avila F (1976) Effect of Adriamycin on DNA, RNA and Protein Synthesis in Cell-Free Systems and Intact Cells. Cancer Res 36: 2891-2895.
38. Michael M, Doherty MM (2005) Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy. JCO 23: 205-229.
39. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, et al. (1997) Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275(5302): 960-963.
40. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67-80.
41. Thomas D, Friedman S, Lin RY (2008) Thyroid stem cells: lessons from normal development and thyroid cancer. Endocr Relat Cancer 15: 51-58.
42. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC, Haugen BR (2008) DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab [Epub ahead of print].
43. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, et al. (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 118(6): 2111-2120.